Omnicell price target lowered to $46 from $54 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on Omnicell (OMCL) to $46 from $54 and keeps a Neutral rating on the shares. While the firm sees “a long runway for mid-single digit growth” given the ongoing industry shift to autonomous pharmacy, there is limited visibility into near-term product revenue growth, the analyst tells investors.